BFEC
PCRX icon

Benjamin F. Edwards & Company’s Pacira BioSciences PCRX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,937
Closed -$144K – 1752
2018
Q3 		$144K Sell
2,937
-889
-23% -$38.4K 0.01% 592
2018
Q2 		$123K Sell
3,826
-2,482
-39% -$85.7K 0.01% 621
2018
Q1 		$196K Buy
6,308
+3,253
+106% +$116K 0.02% 519
2017
Q4 		$139K Buy
3,055
+132
+5% +$5.23K 0.01% 574
2017
Q3 		$110K Buy
2,923
+129
+5% +$5.19K 0.01% 584
2017
Q2 		$133K Buy
2,794
+303
+12% +$14.1K 0.02% 510
2017
Q1 		$114K Buy
2,491
+1,149
+86% +$49.7K 0.02% 527
2016
Q4 		$43K Buy
+1,342
New +$44.8K 0.01% 641
2015
Q3 		– Sell
-200
Closed -$14K – 1181
2015
Q2 		$14K Buy
+200
New +$15.8K ﹤0.01% 855

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Benjamin F. Edwards & Company's PCRX Position: Q4 2018 in Review

Benjamin F. Edwards & Company sold out of Pacira BioSciences (PCRX) in Q4 2018, closing a stake of 2,937 shares — an estimated $144K sold.

Benjamin F. Edwards & Company first reported a position in PCRX in Q2 2015 and held it in 9 quarters. The position peaked at $196K in Q1 2018. 208 funds tracked by Wall St. Rank hold PCRX as of Q4 2018.

  • Benjamin F. Edwards & Company reported no remaining Pacira BioSciences position as of Q4 2018 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 2,937 Pacira BioSciences shares in Q4 2018, an estimated $144K.
  • Benjamin F. Edwards & Company first reported a position in Pacira BioSciences in Q2 2015 and held it in 9 quarters.
  • Benjamin F. Edwards & Company's Pacira BioSciences position peaked at $196K in Q1 2018.
  • 208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2018.

Based on Benjamin F. Edwards & Company's 13F filing for Q4 2018, filed 31 Jan 2019.